Natus Medical Incorporated (NASDAQ:BABY) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Thursday.

A number of other equities analysts have also weighed in on BABY. Benchmark Co. reiterated a “buy” rating and issued a $48.00 price target (down previously from $55.00) on shares of Natus Medical in a research report on Monday, May 1st. Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Finally, TheStreet lowered Natus Medical from a “b” rating to a “c+” rating in a research report on Thursday, April 27th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $45.00.

Shares of Natus Medical (BABY) opened at 32.45 on Thursday. Natus Medical has a 52-week low of $31.65 and a 52-week high of $44.39. The firm has a market capitalization of $1.06 billion, a PE ratio of 56.24 and a beta of 0.93. The company’s 50-day moving average is $35.42 and its 200 day moving average is $36.37.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The business had revenue of $122.20 million during the quarter, compared to analyst estimates of $121.99 million. During the same quarter last year, the company posted $0.39 EPS. Natus Medical’s revenue for the quarter was up 27.3% on a year-over-year basis. Equities analysts expect that Natus Medical will post $1.70 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/26/natus-medical-incorporated-baby-rating-lowered-to-strong-sell-at-bidaskclub.html.

In other Natus Medical news, Director William M. Moore sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total transaction of $102,300.00. Following the completion of the sale, the director now directly owns 30,410 shares in the company, valued at approximately $1,036,981. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James B. Hawkins acquired 4,000 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were acquired at an average price of $33.98 per share, with a total value of $135,920.00. Following the completion of the transaction, the insider now directly owns 578,023 shares in the company, valued at approximately $19,641,221.54. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.

Several large investors have recently made changes to their positions in BABY. Pax World Management LLC raised its stake in shares of Natus Medical by 6.4% in the first quarter. Pax World Management LLC now owns 673,222 shares of the medical equipment provider’s stock valued at $26,424,000 after buying an additional 40,554 shares in the last quarter. Tdam USA Inc. raised its stake in shares of Natus Medical by 78.4% in the first quarter. Tdam USA Inc. now owns 47,977 shares of the medical equipment provider’s stock valued at $1,883,000 after buying an additional 21,087 shares in the last quarter. Karp Capital Management Corp purchased a new stake in shares of Natus Medical during the first quarter valued at about $242,000. Intrust Bank NA raised its stake in shares of Natus Medical by 3.7% in the first quarter. Intrust Bank NA now owns 8,229 shares of the medical equipment provider’s stock valued at $323,000 after buying an additional 295 shares in the last quarter. Finally, Comerica Bank raised its stake in shares of Natus Medical by 3.6% in the first quarter. Comerica Bank now owns 36,642 shares of the medical equipment provider’s stock valued at $1,299,000 after buying an additional 1,289 shares in the last quarter. Institutional investors and hedge funds own 95.66% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.